Resultado de búsqueda
Potassium-competitive acid blockers (P-CABs) inhibit H + ,K + -ATPase in a reversible and K + -competitive manner, and exhibit almost complete inhibition of gastric acid secretion from the first dose. Many pharmaceutical companies have tried to develop P-CABs, but most of their clinical development has been discontinued due to safety concerns ...
14 de jul. de 2023 · Potassium competitive acid blockers (P-CABs) represent an alternative class of drugs to PPIs that reversibly inhibit gastric acid secretion by competing with the K+ on the luminal surface. They rapidly reach high plasma concentrations and are associated with a fast onset of action [ 3 , 4 ].
29 de oct. de 2015 · Background: Potassium-competitive acid blockers (P-CABs), such as tegoprazan, are a new and diverse class of drugs that can completely block the potassium-binding site of gastric H+/K+ ATPase, ...
Core Tip: The potassium-competitive acid blocker (P-CAB) has been discovered as a possible acid suppression therapeutic option.At the enzyme level, P-CABs compete with K + to suppress acid formation; the binding location of these compounds is separate from the probable pocket that K + occupies. When the P-CAB binds to the enzyme, it stops K + from attaching and activating it.
28 de abr. de 2021 · 383 Application of potassium competitive acid blockers in acid-related diseases. Niu CY, Luo XC. BASIC RESEARCH. 389 MiR-484 participates in non-alcoholic fatty liver injury by targeting SIRT1 to ...
1 de feb. de 2018 · Tegoprazan [( S )-4-((5,7-difluorochroman-4-yl)oxy)- N , N ,2-trimethyl-1 H -benzo[d]imidazole-6-carboxamide], a potassium-competitive acid blocker (P-CAB), is a novel potent and highly selective inhibitor of gastric H+/K+-ATPase. Tegoprazan inhibited porcine, canine, and human H+/K+-ATPases in vitro with IC50 values ranging from 0.29 to 0.52 μ M, while that for canine kidney Na+/K+-ATPase ...
8 de nov. de 2023 · TUESDAY, Nov. 7, 2023 -- The U.S. Food and Drug Administration has approved Voquezna (vonoprazan), a novel potassium-competitive acid blocker, as a new treatment for adults for with all grades of erosive esophagitis or erosive gastroesophageal reflux disease (GERD). The approval is based on the results of the PHALCON-EE phase 3 trial, in which ...
